# US 2026/0083850 A1 · Agents and methods for radiation dose enhancement or tumor delineation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083850 A1
- Document ID: US20260083850A1
- Status: Published application
- Kind: A1
- Application number: 19/338,756
- Filed: 2025-09-24
- Published: 2026-03-26
- Earliest claimed: 2024-09-25
- Assignees: University of Connecticut
- Applicants: University of Connecticut
- Inventors: Henry M. Smilowitz; James Hainfeld
- Web page: https://patentgrep.com/patent/US20260083850A1

## CPC

- A61K 41/0038: {Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy (radiotherapy per se A61N5/10)}
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 49/0423: {Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer}
- A61N 5/10: X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence)
- A61P 35/00: Antineoplastic agents
- A61N 2005/1098: {Enhancing the effect of the particle by an injected agent or implanted device}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosure is directed to compounds, compositions, and methods for radiation dose enhancement and the delineation of tumors, and in particular, to improve dose of megavoltage radiation therapy using barium nanoparticles such as BaTiO3 nanoparticles for the delineation of tumors.

## Claims

### Claim 1

A method of enhancing effects of radiation directed to a tissue or a population of cells of a subject in need thereof, comprising:
administering an effective amount of barium nanoparticles to the subject, such that said barium nanoparticles are brought into the vicinity of or into contact with said tissue or a population of cells; and
subjecting the subject to radiation under the presence of said barium nanoparticles.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is mammal.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The method of claim 1, wherein said tissue or said population of cells is tumor.

### Claim 5

(canceled)

### Claim 6 (depends on 4)

The method of claim 4, wherein the solid tumor is selected from the group comprising of prostate cancer, pancreatic cancer, lung cancer, breast cancer, colon cancer, carcinoma, melanoma, sarcomas, lymphoma, and any combination thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the barium nanoparticles are BaTiO3 nanoparticles.

### Claim 8 (depends on 1)

The method of claim 1, wherein the size of the barium nanoparticles are about 1 nm to about 2 nm, about 2 nm to about 3 nm, about 3 nm to about 4 nm, about 4 nm to about 5 nm, about 5 nm to about 10 nm, about 10 nm to about 15 nm, about 15 nm to about 20 nm, about 20 nm to about 25 nm, about 25 nm to about 30 nm, about 30 nm to about 40 nm, about 40 nm to about 50 nm, about 50 nm to about 60 nm, about 60 nm to about 70 nm, about 70 nm to about 80 nm, about 80 nm to about 90 nm, about 90 nm to about 100 nm, about 100 nm to about 150 nm, about 150 nm to about 200 nm, about 200 nm to about 250 nm, about 250 nm to about 300 nm, about 300 nm to about 350 nm, about 350 nm to about 400 nm, about 400 nm to about 450 nm, about 450 nm to about 500 nm.

### Claim 9 (depends on 1)

The method of claim 1, wherein the barium nanoparticles are administered with intravenous, intratumoral, peri-tumoral, intraperitoneal, parenteral, intraprostatic, intrapancreatic, intravesical, intrapulmonary, intramammary, or intracolonic injection, or by any other suitable route.

### Claim at position 10

10-13. (canceled)

### Claim 14 (depends on 1)

The method of claim 1, wherein the effective amount of barium nanoparticles per kilogram of the tumor is about 0.001 g to about 0.002 g, about 0.002 g to about 0.003 g, about 0.003 g to about 0.004 g, about 0.004 g to about 0.005 g, about 0.005 g to about 0.01 g, about 0.01 g to about 0.02 g, about 0.02 g to about 0.03 g, about 0.03 g to about 0.04 g, about 0.04 g to about 0.05 g, about 0.05 g to about 0.1 g, about 0.1 g to about 0.2 g, about 0.2 g to about 0.3 g, about 0.3 g to about 0.4 g, about 0.4 g to about 0.5 g, about 0.5 g to about 1.0 g, about 1.0 g to about 2.0 g, about 2.0 g to about 3.0 g, about 3.0 g to about 4.0 g, about 4.0 g to about 5.0 g, about 5.0 g to about 6.0 g, about 6.0 g to about 7.0 g, about 7.0 g to about 8.0 g, about 8.0 g to about 9.0 g, about 9.0 g to about 10.0 g, about 10.0 g to about 20.0 g, about 20.0 g to about 30.0 g, about 30.0 g to about 40.0 g, about 40.0 g to about 50.0 g, about 50.0 g to about 60.0 g, about 60.0 g to about 70.0 g, about 70.0 g to about 80.0 g, about 80.0 g to about 90.0 g, or about 90.0 g to about 100.0 g.

### Claim 15 (depends on 1)

The method of claim 1, wherein the radiation is X-ray, laser light, microwave, particle beam, or gamma ray.

### Claim at position 13

16-18. (canceled)

### Claim 19 (depends on 15)

The method of claim 15, wherein the radiation is X-ray, and wherein the X-ray is about 1 keV to about 2 keV, about 2 keV to about 4 keV, about 4 keV to about 6 keV, about 6 keV to about 8 keV, about 8 keV to about 10 keV, about 10 keV to about 20 keV, about 20 keV to about 40 keV, about 40 keV to about 60 keV, about 60 keV to about 80 keV, about 80 keV to about 100 keV, about 100 keV to about 1000 keV, about 1000 keV to about 5000 keV, about 5000 keV to about 10,000 keV, about 10,000 keV to about 25,000 keV, about 25,000 keV to about 50,000 keV, about 50,000 keV to about 75,000 keV, about 75,000 keV to about 100,000 keV, about 100,000 keV to about 200,000 keV, about 200,000 keV to about 300,000 keV, about 300,000 keV to about 400,000 keV, about 400,000 keV to about 500,000 keV, about 500,000 keV to about 600,000 keV, about 600,000 keV to about 700,000 keV, about 700,000 keV to about 800,000 keV, about 800,000 keV to about 900,000 keV, about 1 MeV to about 2 MeV, about 2 MeV to about 3 MeV, about 3 MeV to about 4 MeV, about 4 MeV to about 5 MeV, about 5 MeV to about 6 MeV, about 6 MeV to about 7 MeV, about 7 MeV to about 8 MeV, about 8 MeV to about 9 MeV, about 9 MeV to about 10 MeV, about 10 MeV to about 15 MeV, about 15 MeV to about 20 MeV, about 20 MeV to about 25 MeV, about 25 MeV to about 30 MeV, about 30 MeV to about 35 MeV, about 35 MeV to about 40 MeV, about 40 MeV to about 45 MeV, about 45 MeV to about 50 MeV, or about 50 MeV to about 100 MeV.

### Claim at position 15

20-40. (canceled)

### Claim 41

A method of treating cancer in a subject in need thereof, the method comprising:
administering an effective amount of barium nanoparticles or a composition including barium nanoparticles to the subject; and
administering radiotherapy to the said subject.

### Claim 42 (depends on 41)

The method of claim 41, wherein the subject is mammal.

### Claim 43

(canceled)

### Claim 44 (depends on 41)

The method of claim 41, wherein the cancer is selected from the group comprising of prostate cancer, pancreatic cancer, lung cancer, breast cancer, colon cancer, carcinoma, melanoma, sarcomas, lymphoma, and any combination thereof.

### Claim 45 (depends on 41)

The method of claim 41, wherein the barium nanoparticles are BaTiO3 nanoparticle.

### Claim 46 (depends on 41)

The method of claim 41, wherein the size of the barium nanoparticles are about 1 nm to about 2 nm, about 2 nm to about 3 nm, about 3 nm to about 4 nm, about 4 nm to about 5 nm, about 5 nm to about 10 nm, about 10 nm to about 15 nm, about 15 nm to about 20 nm, about 20 nm to about 25 nm, about 25 nm to about 30 nm, about 30 nm to about 40 nm, about 40 nm to about 50 nm, about 50 nm to about 60 nm, about 60 nm to about 70 nm, about 70 nm to about 80 nm, about 80 nm to about 90 nm, about 90 nm to about 100 nm, about 100 nm to about 150 nm, about 150 nm to about 200 nm, about 200 nm to about 250 nm, about 250 nm to about 300 nm, about 300 nm to about 350 nm, about 350 nm to about 400 nm, about 400 nm to about 450 nm, about 450 nm to about 500 nm.

### Claim 47 (depends on 41)

The method of claim 41, wherein the barium nanoparticles are administered with intravenous, intratumoral, peri-tumoral, intraperitoneal, parenteral, intraprostatic, intrapancreatic, intravesical, intrapulmonary, intramammary, or intracolonic injection, or by any other suitable route.

### Claim at position 23

48-51. (canceled)

### Claim 52 (depends on 41)

The method of claim 41, wherein the effective amount of barium nanoparticles per kilogram of the tumor is about 0.001 g to about 0.002 g, about 0.002 g to about 0.003 g, about 0.003 g to about 0.004 g, about 0.004 g to about 0.005 g, about 0.005 g to about 0.01 g, about 0.01 g to about 0.02 g, about 0.02 g to about 0.03 g, about 0.03 g to about 0.04 g, about 0.04 g to about 0.05 g, about 0.05 g to about 0.1 g, about 0.1 g to about 0.2 g, about 0.2 g to about 0.3 g, about 0.3 g to about 0.4 g, about 0.4 g to about 0.5 g, about 0.5 g to about 1.0 g, about 1.0 g to about 2.0 g, about 2.0 g to about 3.0 g, about 3.0 g to about 4.0 g, about 4.0 g to about 5.0 g, about 5.0 g to about 6.0 g, about 6.0 g to about 7.0 g, about 7.0 g to about 8.0 g, about 8.0 g to about 9.0 g, about 9.0 g to about 10.0 g, about 10.0 g to about 20.0 g, about 20.0 g to about 30.0 g, about 30.0 g to about 40.0 g, about 40.0 g to about 50.0 g, about 50.0 g to about 60.0 g, about 60.0 g to about 70.0 g, about 70.0 g to about 80.0 g, about 80.0 g to about 90.0 g, or about 90.0 g to about 100.0 g.

### Claim 53 (depends on 41)

The method of claim 41, wherein radiation of the radiotherapy is X-ray, laser light, microwave, particle beam, or gamma ray.

### Claim at position 26

54-56. (canceled)

### Claim 57 (depends on 41)

The method of claim 41, wherein the radiation is X-ray, and wherein the X-ray is about 1 keV to about 2 keV, about 2 keV to about 4 keV, about 4 keV to about 6 keV, about 6 keV to about 8 keV, about 8 keV to about 10 keV, about 10 keV to about 20 keV, about 20 keV to about 40 keV, about 40 keV to about 60 keV, about 60 keV to about 80 keV, about 80 keV to about 100 keV, about 100 keV to about 1000 keV, about 1000 keV to about 5000 keV, about 5000 keV to about 10,000 keV, about 10,000 keV to about 25,000 keV, about 25,000 keV to about 50,000 keV, about 50,000 keV to about 75,000 keV, about 75,000 keV to about 100,000 keV, about 100,000 keV to about 200,000 keV, about 200,000 keV to about 300,000 keV, about 300,000 keV to about 400,000 keV, about 400,000 keV to about 500,000 keV, about 500,000 keV to about 600,000 keV, about 600,000 keV to about 700,000 keV, about 700,000 keV to about 800,000 keV, about 800,000 keV to about 900,000 keV, about 1 MeV to about 2 MeV, about 2 MeV to about 3 MeV, about 3 MeV to about 4 MeV, about 4 MeV to about 5 MeV, about 5 MeV to about 6 MeV, about 6 MeV to about 7 MeV, about 7 MeV to about 8 MeV, about 8 MeV to about 9 MeV, about 9 MeV to about 10 MeV, about 10 MeV to about 15 MeV, about 15 MeV to about 20 MeV, about 20 MeV to about 25 MeV, about 25 MeV to about 30 MeV, about 30 MeV to about 35 MeV, about 35 MeV to about 40 MeV, about 40 MeV to about 45 MeV, about 45 MeV to about 50 MeV, or about 50 MeV to about 100 MeV.

### Claim at position 28

58-61. (canceled)

### Claim 62

A pharmaceutical composition comprising:
(1) an effective amount of barium nanoparticles; and
(2) at least one pharmaceutical carrier and/or excipient.

### Claim at position 30

63-97. (canceled)
